New Covid drug may work against all mutations of Omicron variant, latest data suggest

New Covid drug may work against all mutations of Omicron variant, latest data suggest

  • Laboratory studies have shown that sotrovimab is effective against 37 known mutations of new strain
  • Data from last week indicated that the drug has several key mutations of Omicron. can fight
  • New data means the treatment will work against the variant in all its forms
  • Drug was approved last week after it was revealed it reduced hospitalizations and deaths by 79 percent in patients with mild to moderate Covid symptoms



<!–

<!–

<!–<!–

<!–

<!–

<!–

According to new data, treatment with COVID antibodies has been shown to work against all mutations of the Omicron variant.

Laboratory studies have shown that the drug, called sotrovimab and developed by British pharmaceutical giant GlaxoSmithKline with US company Vir Biotechnology, is effective against the 37 currently known mutations of the new strain.

Data from last week showed that sotrovimab was able to fight several key mutations of Omicron. But the new data means the treatment will work against the variant in all its forms.

And the drug was approved last week by the UK’s medicines and healthcare products regulatory agency after studies showed it reduced the risk of hospitalization and death in patients with mild to moderate Covid symptoms by 79 percent.

Laboratory studies have shown that the drug, called sotrovimab and developed by British pharmaceutical giant GlaxoSmithKline with US company Vir Biotechnology, is effective against the 37 currently known mutations of the new strain.

Laboratory studies have shown that the drug, called sotrovimab and developed by British pharmaceutical giant GlaxoSmithKline with US company Vir Biotechnology, is effective against the 37 currently known mutations of the new strain.

Sotrovimab, sold under the brand name Xevudy, is used to prevent people from developing severe cases of Covid and is helpful for people with suppressed immune systems. It gives the body Covid antibodies to fight the disease, while antivirals interfere with how the virus reproduces.

The UK government has already ordered around 100,000 doses.

The MHRA authorization means it has now approved two antibody treatments, Ronapreve and Xevudy, and one antiviral, Lagevrio, also known as molnupiravir.

The new data is likely to be greeted with relief by many public health experts amid lingering uncertainty about whether existing Covid-19 vaccines and treatments can effectively fight back against Omicron.

There was also a second dose of good news, with a plant-based Covid-19 vaccine developed by GSK along with Canadian biotech Medicago, which has been shown to be 71 percent effective against several variants of Covid-19 and 75 percent effective against the disease. highly contagious Delta. deformation.

The study also found that there were no serious side effects to the vaccine in the 24,000 people involved in the study

The study also found that there were no serious side effects to the vaccine in the 24,000 people involved in the study

The study also found that there were no serious side effects to the vaccine in the 24,000 people involved in the study

The trial also showed that there were no serious side effects to the vaccine in the 24,000 people involved in the study.

As a result of the data, GSK and Medicago plan to seek approval for the jab from Canadian regulators soon.

If given the green light, it will become the world’s first plant-based Covid-19 vaccine approved for human use.

Herbal medicines can be produced quickly and in large quantities, making them useful for mass public health and vaccination campaigns.

The GSK-Medicago vaccine can also be stored at refrigerator temperature, making it easier to transport than some existing vaccines, such as those developed by Pfizer and BioNTech, which must be stored at -70 degrees Celsius.

Advertisement

.